Citations

Clear

2117 citation(s) found for "Mayo, Steven".

Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Ettinger, David S. , Wood, Douglas E. , Aisner, Dara L. , Akerley, Wallace , Bauman, Jessica R. , Bruno, Débora S. , Chirieac, Lucian R. , D’Amico, Thomas A., DeCamp, Malcolm M., Dilling, Thomas J. , Dowell, Jonathan E. , Gettinger, Scott , Gubens, Matthew A. , Lackner, Rudy P., Maldonado, Fabien , Morgensztern, Daniel , Ng, Thomas, Otterson, Gregory A. , Pacheco, Jose M., Patel, Sandip Pravin , Riely, Gregory J. , Riess, Jonathan W. , Shapiro, Theresa A. , Singh, Aditi P. , Stevenson, James, Tam, Alda L. , Yang, Stephen C. , Yau, Edwin , Gregory, Kristina M., Hughes, Miranda, Schild, Steven E. , Bharat, Ankit , Chang, Joe Y. , Grotz, Travis E. , Hegde, Aparna , Lanuti, Michael D. , Lin, Jules , Loo, Billy W. , Lovly, Christine Marie , Massarelli, Erminia , Tanvetyanon, Tawee , Yanagawa, Jane

Mayo Clinic

Journal of the National Comprehensive Cancer Network | May 11, 2022 | Volume: 20 | Issue: 5 | Pages: 497-530

10.6004/jnccn.2022.0025 | PMID 35545176 Get It

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell Lung Cancer (NSCLC) provide recommended management for patients with NSCLC, including diagnosis, primary treatment, surveillance for relapse, and subsequent treatment. Patients with metastatic lung cancer who are eligible for targeted therapies or immunotherapies are now surviving longer. This selection from the NCCN Guidelines for NSCLC focuses on targeted therapies for patients with metastatic NSCLC and actionable mutations.
Racial Disparities in the Use of Peripheral Nerve Blocks for Postoperative Analgesia After Total Mastectomy: A Retrospective Cohort Study
Mazzeffi, Michael , Teal, Christine, Douglas, Rundell, Starks, Vanessa, Chow, Jonathan H. , Keneally, Ryan J. , Porter, Steven B.

Mayo Clinic

Anesthesia & Analgesia | May 6, 2022 | Volume: 135 | Issue: 1 | Pages: 170-177

10.1213/ane.0000000000006058 | PMID 35522889 Get It

BACKGROUND: Peripheral nerve blocks (PNBs) are used to provide postoperative analgesia after total mastectomy. PNBs improve patient satisfaction and decrease postoperative opioid use, nausea, and vomiting. Few studies have examined whether there is racial-ethnic disparity in the use of PNBs for patients having total mastectomy. We hypothesized that non-Hispanic Asian, non-Hispanic Black, non-Hispanic patients of other races, and Hispanic patients would be less likely to receive a PNB for postoperative analgesia compared to non-Hispanic White patients having total mastectomy. Secondarily, we hypothesized that PNBs would be associated with reduced odds of major complications after total mastectomy. METHODS: We performed a retrospective cohort study using National Surgical Quality Improvement Program (NSQIP) data from 2015 to 2019. Patients were included if they underwent total mastectomy under general anesthesia. Unadjusted rates of PNB use were compared between race-ethnicity groups. Multivariable logistic regression was performed to determine whether race-ethnicity group was independently associated with receipt of a PNB for postoperative analgesia. Secondarily, we calculated crude and risk-adjusted odds ratios for major complications in patients who received a PNB. RESULTS: There were 64,103 patients who underwent total mastectomy and 4704 (7.3%) received a PNB for postoperative analgesia. Patients who received a PNB were younger, more commonly women, were less likely to have diabetes and hypertension, and had less disseminated cancer (all P < .05). In our regression analysis, the odds of receiving a PNB differed significantly by race-ethnicity group ( P < .001). Non-Hispanic Asian and non-Hispanic Black patients had reduced odds of receiving a PNB compared to non-Hispanic White patients (odds ratio [OR], 0.41; 95% confidence interval [CI], 0.33–0.49 and OR, 0.37 [0.32–0.44]), respectively. Non-Hispanic patients of other races, including American Indian, Alaskan Native, and Pacific Islander, also had reduced odds of receiving a PNB (OR, 0.73 [95% CI, 0.64–0.84]) compared to non-Hispanic White patients, as did Hispanic patients (OR, 0.62 [0.56–0.69]). Patients who received a PNB did not have reduced odds of major complications after mastectomy (crude OR, 0.83 [0.65–1.08]; P = .17 and adjusted OR, 0.85 [0.65–1.10]; P = .21). CONCLUSIONS: Significant disparity exists in the use of PNBs for postoperative analgesia in patients of different race-ethnicity who undergo total mastectomy in the United States. Continued efforts are needed to better understand the causes of disparity and to ensure equitable access to PNBs.
Abstract 8915: Unsupervised Machine Learning Clustering Identifies Low Flow-Low Gradient as High Mortality Risk Phenotypes in Transcatheter Aortic Valve Replacement Patients
Wu, Han-Lun, Rayfield, Corbin, Barry, Timothy , Fatunde, Olubadewa A. , Seri, Amith Reddy , Eleid, Mackram F. , Fortuin, F. David , Sweeney, John P., Pollak, Peter , Sabbagh, Abdallah El , Lester, Steven J., Holmes, David R. , Shen, Win K., Patel, Bhavik N. , Chao, Chieh‐Ju , Agasthi, Pradyumna , Arsanjani, Reza

Mayo Clinic

Circulation | April 28, 2022 | Volume: 144 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.144.suppl_1.8915 Get It

Introduction: Multiple supervised machine learning (ML) models have been used to assess the outcomes in patients who underwent transcatheter aortic valve replacement (TAVR) procedure, however, supervised ML requires significant expert time for annotation and labeling. Unsupervised ML can provide insight into the dataset without this process. Hypothesis: We hypothesized that unsupervised k-means ML can identify distinct phenogroups in TAVR patients that can predict prognosis without a priori knowledge. Methods: A retrospective study of patients who underwent TAVR (Jan 2012-Dec 2017) at Mayo Clinic sites was performed. Baseline demographics, EKG, cardiac computed tomography, and echocardiographic data were abstracted. Variables with ≥ 20% missing data were excluded. Prior to the k-means clustering algorithm, principal component analysis was used for dimensionality reduction. Input variables were analyzed according to k-means determined clusters. Kaplan-Meier survival analysis was used to assess the survival of each cluster. Results: A total of 1071 consecutive patients were included in the final analysis. A total of 141 unique variables were used. The mean age was 80.7±8.6 years, 58.2% were male. Patients were divided into 2 distinct phenogroups. In the two phenogroups, cluster 0 (n=639) has significantly better survival than cluster 1 (n= 432) (log-rank p=0.0002) (Figure 1). Cluster 1 has features of low flow-low gradient (LFLG) hemodynamic profile, including lower systolic blood pressure, mean aortic valve gradient, peak aortic valve velocity, and worse LV ejection fraction. Conclusions: Unsupervised ML can identify distinct phenotype features with prognostic significance in TAVR patients. Our results suggest that patients with LFLG hemodynamic features are intrinsically different from other TAVR patients and require more attention to avoid adverse outcomes.
Ultrasound-Guided Gluteal Fascial Plane Block for the Treatment of Chronic Refractory Greater Trochanteric Pain Syndrome — Technique Description and Anatomical Correlation Study
Ferreira‐Dos‐Santos, Guilherme , Hurdle, Mark Friedrich B., Tran, John , Eldrige, Jason S. , Clendenen, Steven R. , Agur, Anne Maria Reet

Mayo Clinic

Pain Medicine | April 26, 2022 | Volume: 23 | Issue: 11 | Pages: 1875-1881

10.1093/pm/pnac071 | PMID 35511153 Get It

Abstract Introduction Greater trochanteric pain syndrome may often mimic pain generated from other sources. However, it is most commonly caused by gluteus medius and gluteus minimus tendinopathy or tear. The purpose of this technical report was to: 1) describe the ultrasound-guided fascial plane block technique targeting the superior gluteal nerve in the plane between gluteus medius/gluteus minimus to treat moderate-to-severe, chronic, refractory greater trochanteric pain syndrome; 2) anatomically correlate the procedure with cadaveric dissections demonstrating the structures being imaged and the tissues along the needle trajectory; 3) demonstrate the feasibility of the technique with serial dissection of one cadaveric specimen following injection with color dye. Technique description The ultrasound-guided fascial plane block targeting the superior gluteal nerve to treat moderate-to-severe, chronic, refractory greater trochanteric pain syndrome has been outlined with supporting ultrasound scans and anatomical dissections. The cadaveric dissections are correlated to the ultrasound scans of a healthy volunteer and provide visualization of the tissues in the needle trajectory. The feasibility study in a cadaveric specimen showed adequate stain of the superior gluteal nerve without spread to the piriformis muscle belly, the sciatic nerve, or the inferior gluteal nerve. Conclusions This ultrasound-guided fascial plane block is a feasible option for blocking the superior gluteal nerve without inadvertent involvement of the sciatic and inferior gluteal nerves. Further randomized controlled clinical trials are necessary to assess the clinical efficacy of the gluteus medius/gluteus minimus fascial plane block to treat moderate-to-severe, chronic, refractory greater trochanteric pain syndrome.
GPU‐accelerated Monte Carlo‐based online adaptive proton therapy: A feasibility study
Feng, Hongying , Patel, Samir H. , Wong, William W. , Younkin, James E. , Penoncello, Gregory P. , Morales, Danairis Hernandez, Stoker, J. , Robertson, Daniel , Fatyga, M., Foote, Robert L. , Stoker, Joshua B., Robertson, Daniel G, Fatyga, Mirek, Bues, Martin , Schild, Steven E. , Penoncello, Gregory , Liu, Wei

Mayo Clinic

Medical Physics | April 20, 2022 | Volume: 49 | Issue: 6 | Pages: 3550-3563

10.1002/mp.15678 | PMID 35443080 Get It

AbstractPurposeTo develop an online graphic processing unit (GPU)‐accelerated Monte Carlo‐based adaptive radiation therapy (ART) workflow for pencil beam scanning (PBS) proton therapy to address interfraction anatomical changes in patients treated with PBS.Methods and MaterialsA four‐step workflow was developed using our in‐house developed GPU‐accelerated Monte Carlo‐based treatment planning system to implement online Monte Carlo‐based ART for PBS. The first step conducts diffeomorphic demon‐based deformable image registration (DIR) to propagate contours on the initial planning CT (pCT) to the verification CT (vCT) to form a new structure set. The second step performs forward dose calculation of the initial plan on the vCT with the propagated contours after manual approval (possible modifications involved). The third step triggers a reoptimization of the plan depending on whether the verification dose meets the clinical requirements or not. A robust evaluation will be done for both the verification plan in the second step and the reopotimized plan in the third step. The fourth step involves a two‐stage (before and after delivery) patient‐specific quality assurance (PSQA) of the reoptimized plan. The before‐delivery PSQA is to compare the plan dose to the dose calculated using an independent fast open‐source Monte Carlo code, MCsquare. The after‐delivery PSQA is to compare the plan dose to the dose recalculated using the log file (spot MU, spot position, and spot energy) collected during the delivery. Jaccard index (JI), dice similarity coefficients (DSCs), and Hausdorff distance (HD) were used to assess the quality of the propagated contours in the first step. A commercial plan evaluation software, ClearCheck™, was integrated into the workflow to carry out efficient plan evaluation. 3D Gamma analysis was used during the fourth step to ensure the accuracy of the plan dose from reoptimization. Three patients with three different disease sites were chosen to evaluate the feasibility of the online ART workflow for PBS.ResultsFor all three patients, the propagated contours were found to have good volume conformance [JI (lowest‐highest: 0.833–0.983) and DSC (0.909–0.992)] but suboptimal boundary coincidence [HD (2.37–20.76 mm)] for organs‐at‐risk. The verification dose evaluated by ClearCheck™ showed significant degradation of the target coverage due to the interfractional anatomical changes. Reoptimization on the vCT resulted in great improvement of the plan quality to a clinically acceptable level. 3D Gamma analyses of PSQA confirmed the accuracy of the plan dose before delivery (mean Gamma index = 98.74% with a threshold of 2%/2 mm/10%), and after delivery based on the log files (mean Gamma index = 99.05% with a threshold of 2%/2 mm/10%). The average time cost for the complete execution of the workflow was around 858 s, excluding the time for manual intervention.ConclusionThe proposed online ART workflow for PBS was demonstrated to be efficient and effective by generating a reoptimized plan that significantly improved the plan quality.
Portal fibroblasts: A renewable source of liver myofibroblasts
O’Hara, Steven P. , LaRusso, Nicholas F.

Mayo Clinic

Hepatology | April 16, 2022 | Volume: 76 | Issue: 5 | Pages: 1240-1242

10.1002/hep.32528 | PMID 35429172 Get It

Pediatric pineoblastoma: A pooled outcome study of North American and Australian therapeutic data
Hansford, Jordan R. , Huang, Jie , Endersby, Raelene , Dodgshun, Andrew , Li, Bryan , Hwang, Eugene , Gajjar, Amar , Hoff, Katja von , Wells, Olivia, Wray, Alison, Kotecha, Rishi S. , Raleigh, David R. , Stoller, Schuyler , Mueller, Sabine , Bandopadhayay, Pratiti , Fouladi, Maryam , Onar‐Thomas, Arzu , Gottardo, Nicholas G. , Von Hoff, Katja , Mueller, Sabine , Schild, Steven E. , Fouladi, Maryam , Bouffet, Eric , Hansford, Jordan R , Leary, Sarah , Bouffet, Éric , Huang, Annie

Mayo Clinic

Neuro-Oncology Advances | April 14, 2022 | Volume: 4 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdac056 | PMID 35664557 Get It

Abstract Background Pineoblastoma is a rare brain tumor usually diagnosed in children. Given its rarity, no pineoblastoma-specific trials have been conducted. Studies have included pineoblastoma accruing for other embryonal tumors over the past 30 years. These included only occasional children with pineoblastoma, making clinical features difficult to interpret and determinants of outcome difficult to ascertain. Patients and Methods Centrally or independently reviewed series with treatment and survival data from North American and Australian cases were pooled. To investigate associations between variables, Fisher’s exact tests, Wilcoxon-Mann-Whitney tests, and Spearman correlations were used. Kaplan-Meier plots, log-rank tests, and Cox proportional hazards models were used in survival analyses. Results We describe a pooled cohort of 178 pineoblastoma cases from Children’s Oncology Group (n = 82) and institutional series (n = 96) over 30 years. Children &lt;3 years of age have significantly worse survival compared to older children, with 5-year progression-free survival (PFS) and overall survival (OS) estimates of 13.5 ± 5.1% and 16.2 ± 5.3%, respectively, compared with 60.8 ± 5.6% and 67.3 ± 5.0% for ≥3 years old (both P &lt; .0001). Multivariable analysis showed male sex was associated with worse PFS in children &lt;3 years of age (hazard ratio [HR] 3.93, 95% CI 1.80-8.55; P = .0006), suggestive of sex-specific risks needing future validation. For children ≥3 years of age, disseminated disease at diagnosis was significantly associated with an inferior 5-year PFS of 39.2 ± 9.7% (HR 2.88, 95% CI 1.52-5.45; P = .0012) and 5-year OS of 49.8 ± 9.1% (HR 2.87, 95% CI 1.49-5.53; P = .0016). Conclusion Given the rarity of this tumor, prospective, collaborative international studies will be vital to improving the long-term survival of these patients.
Ultrasound-Guided Hydrodissection of the Superficial Peroneal Nerve for Chronic Neuropathic Pain: A War Veteran’s Story
Ferreira‐Silva, Nuno , Galacho, João , Ferreira‐Dos‐Santos, Guilherme , Clendenen, Steven R. , Hurdle, Mark Friedrich B., Ferreira-Silva, Nuno

Mayo Clinic

Pain Management | April 13, 2022 | Volume: 12 | Issue: 5 | Pages: 579-586

10.2217/pmt-2022-0014 | PMID 35416721 Get It

Histopathologic features of necrobiosis lipoidica
Johnson, Emma F. , Patel, Meera H. , Brumfiel, Caitlin M. , Severson, Kevin J. , Bhullar, Puneet , Boudreaux, Blake , Butterfield, Richard , DiCaudo, David J. , Nelson, Steven A. , Pittelkow, Mark R. , Mangold, Aaron R. , Johnson, Emma , Mangold, A R

Mayo Clinic

Journal of Cutaneous Pathology | April 11, 2022 | Volume: 49 | Issue: 8 | Pages: 692-700

10.1111/cup.14238 | PMID 35403265 Get It

AbstractBackgroundNecrobiosis lipoidica (NL) is an uncommon granulomatous dermatosis that can occur in patients with or without associated diabetes mellitus (DM). Prior studies have attempted to determine distinctive histopathologic features of NL in patients with and without DM.MethodsA retrospective review of 97 patients with NL was performed to determine the similar and distinctive histopathologic features in patients with DM and without DM.ResultsOf the 97 patients, 32% (n = 31) had DM. Epidermal acanthosis was seen more commonly in diabetics than nondiabetics (32.3% vs. 12.1%; p = 0.017). Naked (sarcoidal/tuberculoid) granulomas were more frequently observed in nondiabetics than diabetics (22.7% vs. 3.2%; p = 0.016). Eosinophils were more common in nondiabetics than diabetics (38.5% vs. 9.7%; p = 0.004), while neutrophilic infiltration was more common in diabetics than nondiabetics (45.2% vs. 17.5%; p = 0.004).ConclusionsThis study corroborates well‐documented histopathologic features of NL and shows distinctive histopathologic features of NL among patients with DM‐I, DM‐II, and without DM. These results support the hypothesis that there are different underlying drivers of NL between diabetics and nondiabetics.
Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial
Gounder, Mrinal M. , Razak, Albiruni Abdul , Somaiah, Neeta , Chawla, Sant P. , Martín‐Broto, Javier , Schuetze, Scott M. , Vincenzi, Bruno , Wagner, Andrew J. , Chmielowski, Bartosz , Jones, Robin L. , Riedel, Richard F. , Stacchiotti, Silvia , Ganjoo, Kristen N. , Cesne, Axel Le , Italiano, Antoîne , Ryan, Christopher W. , Mulcahy, Mary F. , Forscher, Charles, Okuno, Scott H. , Hartner, Lee , Philip, Tony , Alcindor, Thierry , Reichardt, Peter , Chevreau, Christine , Morales, Claudia Maria Valverde, Chen, James L. , Deshpande, Hari A. , Nicholas, Garth , Gröschel, Stefan , Hatcher, Helen, Duffaud, Florence , Beveridge, Roberto Díaz, Meyer, Christian F. , Götze, Katharina S. , Mazzeo, F , Yakobson, Alexander, Zick, Aviad , Lee, Alexander T.J. , Estival, Anna , Napolitano, Andrea , Dickson, Mark A. , Michel, Dayana , Meng, Changting , Ben‐Shahar, Osnat , Chang, Hua, Landesman, Yosef , Shah, Jatin J., Shacham, Sharon, Kauffman, Michael , Attia, Steven , Schuetze, Scott M , Vincenzi, Bruno , Wagner, Andrew J , Chmielowski, Bartosz , Jones, Robin L , Riedel, Richard F , Loggers, Elizabeth T , Le Cesne, Axel , Italiano, Antoine , Garcia Del Muro, Xavier , Mulcahy, Mary F , Penel, Nicolas , Okuno, Scott , Elias, Anthony D , Hartner, Lee , Philip, Tony , Alcindor, Thierry , Lapeire, Lore , Blay, Jean-Yves , Chen, James L , Davis, Elizabeth J , Hatcher, Helen , Meyer, Christian , von Mehren, Margaret , Van Tine, Brian A , Götze, Katharina , Mazzeo, Filomena , Zick, Aviad , Lee, Alexander , Gonzalez, Anna Estival , Napolitano, Andrea , Michel, Dayana , Meng, Changting , Ben-Shahar, Osnat , Van Domelen, Dane R , Grignani, Giovanni , Burgess, Melissa , Piperno‐Neumann, Sophie , Elias, Anthony , Kasper, Bernd , Blay, Jean‐Yves , Schwartz, Gary K. , Davis, Elizabeth J. , Casado, Antonio , Badalamenti, Giuseppe , Eriksson, Mikael , Mehren, Margaret von , Tine, Brian A. Van , Li, Lingling , Liu, Jianjun , Walker, Christopher James

Mayo Clinic

Journal of Clinical Oncology | April 8, 2022 | Volume: 40 | Issue: 22 | Pages: 2479-2490

10.1200/jco.21.01829 | PMID 35394800 Get It

PURPOSE Antitumor activity in preclinical models and a phase I study of patients with dedifferentiated liposarcoma (DD-LPS) was observed with selinexor. We evaluated the clinical benefit of selinexor in patients with previously treated DD-LPS whose sarcoma progressed on approved agents. METHODS SEAL was a phase II-III, multicenter, randomized, double-blind, placebo-controlled study. Patients age 12 years or older with advanced DD-LPS who had received two-five lines of therapy were randomly assigned (2:1) to selinexor (60 mg) or placebo twice weekly in 6-week cycles (crossover permitted). The primary end point was progression-free survival (PFS). Patients who received at least one dose of study treatment were included for safety analysis (ClinicalTrials.gov identifier: NCT02606461 ). RESULTS Two hundred eighty-five patients were enrolled (selinexor, n = 188; placebo, n = 97). PFS was significantly longer with selinexor versus placebo: hazard ratio (HR) 0.70 (95% CI, 0.52 to 0.95; one-sided P = .011; medians 2.8 v 2.1 months), as was time to next treatment: HR 0.50 (95% CI, 0.37 to 0.66; one-sided P < .0001; medians 5.8 v 3.2 months). With crossover, no difference was observed in overall survival. The most common treatment-emergent adverse events of any grade versus grade 3 or 4 with selinexor were nausea (151 [80.7%] v 11 [5.9]), decreased appetite (113 [60.4%] v 14 [7.5%]), and fatigue (96 [51.3%] v 12 [6.4%]). Four (2.1%) and three (3.1%) patients died in the selinexor and placebo arms, respectively. Exploratory RNA sequencing analysis identified that the absence of CALB1 expression was associated with longer PFS with selinexor compared with placebo (median 6.9 v 2.2 months; HR, 0.19; P = .001). CONCLUSION Patients with advanced, refractory DD-LPS showed improved PFS and time to next treatment with selinexor compared with placebo. Supportive care and dose reductions mitigated side effects of selinexor. Prospective validation of CALB1 expression as a predictive biomarker for selinexor in DD-LPS is warranted.